Fast Market Research recommends "Chile Pharmaceuticals & Healthcare Report Q2 2013" from Business Monitor International, now available
Boston, MA -- (SBWIRE) -- 07/09/2013 -- Chile's improving regulation system should bring high quality medicines to the local market and eventually reduce the country's medical spending. The tightened bioequivalent regulations will boost genuine medicine sales and force similares out of the market. It will also help to bring local drugmakers up to international standards, and in the long term, improve their competitiveness in the domestic and regional markets. Foreign drugmakers with products which have been held to tougher regulation standards in the international market will benefit from the legislation immediately.
Headline Expenditure Projections
- Pharmaceuticals: CLP1,605bn (US$3.3bn) in 2012 to CLP1,723bn (US$3.6bn) in 2013; +8.1% in local currency terms and +7.5% in US dollar terms.
- Healthcare: CLP9,637bn (US$19.8bn) in 2012 to CLP10,550bn (US$22.1bn) in 2013; +9.5% in local currency terms and +11.2% in US dollar terms.
View Full Report Details and Table of Contents
Risk/Reward Rating: Chile's ratings score for Q213 stands at 53.7 out of 100, with the country ranked 7th out of the 17 markets in the Americas matrix. This is also the case for all other countries in BMI's proprietary system, which ranks pharmaceutical markets according to attractiveness to multinational drugmakers. A minor re-weighting of one of the RRR components is being implemented to improve the tool, and the adjusted scores for all markets will be published in the Q313 updates of the Pharmaceuticals & Healthcare reports.
Key Trends And Developments
- In January 2013, the Chilean President, Sebastian Pinera, along with Health Minister, Jaime Manalich, and Deputy Finance Minister, Julio Dittborn, signed a supreme decree on bioequivalent medicines and given authority to the National Medicines Agency (ANAMED) to approve the drugs. The government stated that the new legislation aims to facilitate access to bioequivalent drugs in Chile and reduce medicine prices. The president has planned to increase the number of approved bioequivalent drugs to 3,000 over the next four years. The Institute of Public Health in Chile (ISPCH) will be responsible for the certification of bioequivalence through ANAMED.
- In February 2013, generic pharmaceutical firm Sandoz planned to launch six drugs on the Chilean market in H113. The company will launch omeprazole, which is indicated for gastroesophageal reflux; antihypertensive therapeutic losartan; antidepressant escitalopram; immunosuppressive mycophenolate mofetil; rosuvastatin, which reduces cholesterol levels in the blood; and antithrombotic and antiplatelet agent clopidogrel. The new drugs will help bolster the company's position in the Chilean market, according to Maria Virginia Monsalve, commercial manager at Sandoz's Chile division
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Russia Pharmaceuticals & Healthcare Report Q2 2013
- Jordan Pharmaceuticals & Healthcare Report Q2 2013
- Morocco Pharmaceuticals & Healthcare Report Q2 2013
- Israel Pharmaceuticals & Healthcare Report Q2 2013
- India Pharmaceuticals & Healthcare Report Q2 2013
- Iraq Pharmaceuticals & Healthcare Report Q2 2013
- Saudi Arabia Pharmaceuticals & Healthcare Report Q2 2013
- Estonia Pharmaceuticals & Healthcare Report Q3 2013
- Malaysia Pharmaceuticals & Healthcare Report Q2 2013
- Turkey Pharmaceuticals & Healthcare Report Q2 2013